Drug Shortage Report for CEFAZOLIN FOR INJECTION, USP
Report ID | 105945 |
Drug Identification Number | 02237138 |
Brand name | CEFAZOLIN FOR INJECTION, USP |
Common or Proper name | Cefazolin for Injection |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | CEFAZOLIN |
Strength(s) | 1.0G |
Dosage form(s) | POWDER FOR SOLUTION |
Route of administration | INTRAMUSCULAR INTRAVENOUS |
Packaging size | 1 G |
ATC code | J01DB |
ATC description | OTHER BETA-LACTAM ANTIBACTERIALS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2019-09-27 |
Estimated end date | Unknown |
Actual end date | 2020-05-08 |
Shortage status | Resolved |
Updated date | 2020-07-08 |
Company comments | Remove from allocation |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2020-02-13 | English | Compare |
v2 | 2020-02-13 | French | Compare |
v3 | 2020-02-13 | French | Compare |
v4 | 2020-07-08 | English | Compare |
v5 | 2020-07-08 | French | Compare |
Showing 1 to 5 of 5